Zimmer Biomet Holdings, Inc. $ZBH Stake Lifted by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 257.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 34,370 shares of the medical equipment provider’s stock after acquiring an additional 24,748 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Zimmer Biomet were worth $3,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Border to Coast Pensions Partnership Ltd boosted its position in Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after acquiring an additional 22,104 shares during the period. National Pension Service boosted its position in Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after acquiring an additional 16,928 shares during the period. AMG National Trust Bank boosted its position in Zimmer Biomet by 29.1% during the 3rd quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock worth $4,960,000 after acquiring an additional 11,339 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in Zimmer Biomet by 47.5% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 62,079 shares of the medical equipment provider’s stock worth $6,115,000 after acquiring an additional 19,996 shares during the period. Finally, New York State Common Retirement Fund boosted its position in Zimmer Biomet by 24.9% during the 3rd quarter. New York State Common Retirement Fund now owns 208,503 shares of the medical equipment provider’s stock worth $20,538,000 after acquiring an additional 41,538 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.28% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZBH shares. Citizens Jmp reduced their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Truist Financial restated a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a report on Wednesday, April 29th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. Finally, Leerink Partners initiated coverage on Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $102.80.

Zimmer Biomet Trading Down 0.1%

Shares of Zimmer Biomet stock opened at $85.41 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a market cap of $16.52 billion, a price-to-earnings ratio of 22.19, a price-to-earnings-growth ratio of 1.98 and a beta of 0.48. The business has a fifty day simple moving average of $88.68 and a 200-day simple moving average of $90.79. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.